LAMOTRIGINE HEMIFUMARATE
| Brand name | LAMLIQUE |
|---|---|
| Active ingredient | LAMOTRIGINE HEMIFUMARATE |
| Strength | EQ 5MG BASE/ML |
| Dosage form | SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12605388 | February 2045 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.